4-甲氧基-3-三氟甲基苯硼酸 | 149507-36-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲氧基-3-三氟甲基苯硼酸
• 中文别名: 4-甲氧基-3-三氟甲基苯基硼酸；3-三氟甲基-4-甲氧基苯硼酸
• 英文名称: (4-methoxy-3-(trifluoromethyl)phenyl)boronic acid
• 英文别名: [4-methoxy-3-(trifluoromethyl)phenyl]boronic acid
• CAS: 149507-36-8
• 化学式: C₈H₈BF₃O₃
• mdl: MFCD07363790
• 分子量: 219.956
• InChiKey: BUSMBMGODABSIN-UHFFFAOYSA-N

物化性质

• 熔点：
  198-202
• 沸点：
  321.6±52.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.27
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请保持冷敷。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Methoxy-3-trifluoromethylphenylboronic acid
Product Name:
Synonyms: 4-Methoxy-3-(trifluoromethyl)phenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Methoxy-3-trifluoromethylphenylboronic acid
Ingredient name:
CAS number: 149507-36-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H8BF3O3
Molecular weight: 220.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲氧基-3-三氟甲基苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三溴化硼 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 4-(7-chloroquinolin-4-yl)-2-(trifluoromethyl)phenol
  参考文献：
  名称：

  [EN] BIARYL KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASES À BASE DE BIARYLE

  摘要：

  本公开涉及式(I)的双芳基化合物，该化合物能够抑制AAK1（适配器相关激酶1），包含此类化合物的组合物以及它们用于治疗例如疼痛、阿尔茨海默病、帕金森病和精神分裂症。

  公开号：

  WO2017059085A1
• 作为产物：
  描述：

  4-溴-2-(三氟甲基)苯甲醚 在 正丁基锂 、 硼酸三异丙酯 、 水 、 溶剂黄146 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.33h， 生成 4-甲氧基-3-三氟甲基苯硼酸
  参考文献：
  名称：

  WO2007/39470

  摘要：

  公开号：

文献信息

• [EN] BIARYL KINASE INHIBITORS<br/>[FR] INHIBITEURS BIARYLES DE KINASES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017059080A1

  公开（公告）日：2017-04-06

  The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

  本公开涉及公式（I）的联苯化合物，可以抑制AAK1（适配器相关激酶1），包括这种化合物的组合物以及它们用于治疗疼痛、阿尔茨海默病、帕金森病和精神分裂症等的用途。
• 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
  申请人：Rankovic Zoran

  公开号：US20070111992A1

  公开（公告）日：2007-05-17

  Disclosed herein are 4-phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives having Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims; or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising these 4-phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives and use of these 4-phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives for the treatment of cathepsin K and cathepsin S related disorders, e.g. osteoporosis, atherosclerosis, inflammation and immune disorders such as rheumatoid arthritis and chronic pain.

  本文披露了具有化学式I的4-苯基-6-取代嘧啶-2-碳腈衍生物，其中每个取代基的定义如规范和索赔中所述；或其药学上可接受的盐。还披露了包含这些4-苯基-6-取代嘧啶-2-碳腈衍生物的药物组合物，以及利用这些4-苯基-6-取代嘧啶-2-碳腈衍生物治疗与卡特普辛K和卡特普辛S相关的疾病，例如骨质疏松症、动脉粥样硬化、炎症和风湿性关节炎、慢性疼痛等。
• Discovery of Potent and Selective Leads against <i>Toxoplasma gondii</i> Dihydrofolate Reductase via Structure-Based Design
  作者：Matthew E. Welsch、Jian Zhou、Yueqiang Gao、Yunqing Yan、Gene Porter、Gautam Agnihotri、Yingjie Li、Henry Lu、Zhongguo Chen、Stephen B. Thomas

  DOI：10.1021/acsmedchemlett.6b00328

  日期：2016.12.8

  the design of inhibitors with both improved potency and selectivity. The approach described herein yielded TRC-19, a promising lead with an IC50 of 9 nM and 89-fold selectivity in favor of Toxoplasma gondii DHFR, as well as crystallographic data to substantiate in silico methodology. Overall, 50% of synthesized in silico designs met hit threshold criteria of IC50 < 10 μM and >2-fold selectivity favoring

  弓形虫病的当前治疗通过抑制二氢叶酸还原酶（DHFR）靶向寄生虫的叶酸代谢。最广泛使用的DHFR拮抗剂嘧啶胺是60年前引入的，与毒性相关，在很大程度上可归因于对寄生虫和人DHFR的相似亲和力。弓形虫和人类DHFR之间的生化差异的计算分析使设计的抑制剂具有更高的效能和选择性。本文描述的方法产生了TRC-19，这是一种有前途的潜在客户，其IC 50为9 nM，选择性为弓形虫DHFR的89倍，并提供了晶体学数据以证实计算机模拟方法的正确性。总体而言，合成的50％在计算机设计中，符合IC 50 <10μM且达到2倍选择性的命中阈值标准有利于弓形虫，进一步证明了我们基于结构的药物设计方法的效率。
• Enantioselective Palladium‐Catalyzed Cross‐Coupling of α‐Bromo Carboxamides and Aryl Boronic Acids
  作者：Bowen Li、Tiejun Li、Muinat A. Aliyu、Zhen Hua Li、Wenjun Tang

  DOI：10.1002/anie.201905174

  日期：2019.8.12

  report an enantioselective palladium‐catalyzed cross‐coupling between α‐bromo carboxamides and aryl boronic acids, generating a series of chiral α‐aryl carboxamides in good yields and excellent enantioselectivities. The development of a chiral P,P=O ligand was critical in overcoming the second transmetalation issue and allows the first asymmetric palladium‐catalyzed coupling of α‐bromo carbonyl compounds

  我们在本文中报道了α-溴羧酰胺与芳基硼酸之间的对映选择性钯催化的交叉偶联，以高收率和优异的对映选择性产生了一系列手性α-芳基羧酰胺。手性P，P = O配体的发展对于克服第二个金属转移问题至关重要，并且可以实现α-溴代羰基化合物的第一个不对称钯催化偶联。
• [EN] BIARYL KINASE INHIBITORS<br/>[FR] INHIBITEURS BIARYLE DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015153720A1

  公开（公告）日：2015-10-08

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开通常涉及能够抑制AAK1（适配器相关激酶1）的化合物、包含该化合物的组合物以及抑制AAK1的方法。